Updated:
Tempus AI
Tempus AI builds an AI-driven clinical data platform for precision medicine, partnering with academic centers and biopharma out of Chicago.
Tempus AI
Tempus AI was founded to infuse data-driven decision-making into patient care, assembling vast libraries of de-identified clinical and genomic records. The firm's platform ingests, cleans, and structures multimodal data from partner hospitals and labs, then layers on AI-powered tools for research, drug development, and treatment selection. This approach places it squarely between a healthcare-focused technology company and a data licensor for the life sciences industry. The investment strategy centers on expanding a data-and-software ecosystem that connects diagnostics, clinical records, and therapeutic discovery. Tempus has built a sequencing and pathology lab network that generates molecular data, which in turn feeds its machine-learning models. The firm deploys capital into lab infrastructure, data partnerships with major academic cancer centers, and software tools that support clinical trial matching and cohort identification for pharmaceutical clients. Its platform serves oncologists, researchers, and biopharma companies seeking to accelerate drug development timelines. Operating from Chicago, the firm has grown through successive financing rounds backed by prominent technology and life sciences investors. In recent years, Tempus extended its reach beyond oncology into neuropsychiatry, cardiology, and infectious disease, broadening its data moat. The company has also pursued partnerships with national health systems and expanded its commercial team to serve global biopharma accounts. Tempus AI's structural distinction lies in its vertically integrated model: it does not license third-party datasets as its primary input but instead generates proprietary clinical and molecular data through its own lab business. This creates a feedback loop where each new patient sample strengthens the predictive models, which in turn increases the platform's utility for drug developers — a cycle that competitor analytics firms without a lab footprint cannot easily replicate.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Chicago
Corporate office
Chicago, IL, United States
Sector focus
Frequently asked questions
What does Tempus AI actually do?
Tempus structures and analyzes clinical and molecular data to help physicians make personalized treatment decisions and to accelerate pharmaceutical research. It operates a sequencing lab that generates genomic data from tumor and liquid biopsies, then pairs that data with structured electronic health records. The resulting analytics platform supports clinical trial matching, therapeutic discovery, and diagnostic development.
How does Tempus source its data?
Tempus builds proprietary data pipelines through direct partnerships with academic medical centers, community hospitals, and health systems. These partners contribute de-identified clinical records and biological samples that Tempus sequences in its own labs. This vertically integrated model generates real-world data that is deeper and more structured than what typical aggregators license from third parties.
Is Tempus AI a diagnostics company or a software company?
Tempus operates as both, which is central to its strategy. The diagnostics arm runs a high-throughput sequencing and pathology lab that produces clinical test results and fuels a growing molecular database. The software arm builds AI-powered tools on top of that data, selling analytics and trial-matching capabilities to life sciences companies. The lab and software businesses are designed to reinforce each other.
Which sectors and disease areas does Tempus focus on?
Oncology is the company's foundational vertical, covering solid tumors and hematologic malignancies. Tempus has expanded into neuropsychiatry, cardiology, and infectious disease, applying similar data-structuring methods to different patient populations. Within each disease area, the firm targets diagnostic testing, real-world evidence generation, and clinical trial tools.
Who are Tempus AI's known investors or financial backers?
Tempus has raised capital from prominent technology and life sciences investors across multiple private financing rounds, though specific current investors and stakes have shifted over time. The firm has not operated as a single-family office or a dedicated pooled fund vehicle; its capital structure reflects venture and growth equity backing common to late-stage health-tech platforms.
Does Tempus participate in drug development directly?
Tempus does not develop its own therapeutic candidates. It operates as an infrastructure and data partner to biopharma companies, providing analytics, patient cohort identification, and real-world data services that support clinical development and regulatory submissions. Its revenue is generated from diagnostic tests, data licensing, and software subscriptions.
What is the known scale of Tempus AI's operations?
Tempus has assembled one of the largest linked clinical-and-genomic databases in oncology, with millions of de-identified patient records and a growing volume of sequenced samples. The company's physical footprint includes a central lab in Chicago and network partnerships across the United States. Exact current deployment figures and headcount have varied as the firm has expanded its therapeutic-area coverage.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: